相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Pyridine Moiety: An Insight into Recent Advances in the Treatment of Cancer
Rakesh Sahu et al.
MINI-REVIEWS IN MEDICINAL CHEMISTRY (2022)
Molecular Targets in Cholangiocarcinoma
Colm J. O'Rourke et al.
HEPATOLOGY (2021)
FGFR-targeted therapy in head and neck carcinomas
Dimo Dietrich
HNO (2021)
Futibatinib, an investigational agent for the treatment of intrahepatic cholangiocarcinoma: evidence to date and future perspectives
Alessandro Rizzo et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2021)
Near-infrared photoimmunotherapy (NIR-PIT) on cholangiocarcinoma using a novel catheter device with light emitting diodes
Hajime Hirata et al.
CANCER SCIENCE (2021)
Nivolumab: an investigational agent for the treatment of biliary tract cancer
Alessandro Di Federico et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2021)
Infigratinib (BGJ398): an investigational agent for the treatment of FGFR-altered intrahepatic cholangiocarcinoma
Gehan Botrus et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2021)
Phase II trial of the PARP inhibitor, niraparib, in BRCA1-Associated Protein 1 (BAP1) and other DNA damage response (DDR) pathway deficient neoplasms including cholangiocarcinoma.
Thomas J. George et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Long non-coding RNA LINC00665 promotes gemcitabine resistance of Cholangiocarcinoma cells via regulating EMT and stemness properties through miR-424-5p/BCL9L axis
Min Lu et al.
CELL DEATH & DISEASE (2021)
Fibroblast growth factor receptor (FGFR) inhibitors: A review of a novel therapeutic class
April Weaver et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2021)
Defining and Targeting BRAF Mutations in Solid Tumors
Briana R. Halle et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2021)
Targeting FGFR in intrahepatic cholangiocarcinoma [iCCA]: leading the way for precision medicine in biliary tract cancer [BTC]?
Gabriella Aitcheson et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2021)
Cholangiocarcinoma: shedding light on the most promising drugs in clinical development
Amir A. Rahnemai-Azar et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2021)
Randomized Phase II trial of combination chemotherapy with panitumumab or bevacizumab for patients with inoperable biliary tract cancer without KRAS exon 2 mutations
Nadia Emad Lotfi Amin et al.
INTERNATIONAL JOURNAL OF CANCER (2021)
Derazantinib for patients with intrahepatic cholangiocarcinoma harboring FGFR2 fusions/rearrangements: Primary results from the phase II study FIDES-01
M. Droz Dit Busset et al.
ANNALS OF ONCOLOGY (2021)
Apatinib as non-first-line treatment in patients with Intrahepatic Cholangiocarcinoma
Jinzhu Mao et al.
JOURNAL OF CANCER (2021)
Clinical Efficacy of Olaparib in IDH1/IDH2-Mutant Mesenchymal Sarcomas
Joseph P. Eder et al.
JCO PRECISION ONCOLOGY (2021)
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study
Ghassan K. Abou-Alfa et al.
LANCET ONCOLOGY (2020)
An insight into primary biliary cholangitis and its recent advances in treatment: semi-synthetic analogs to combat ursodeoxycholic-acid resistance
Rakesh Sahu et al.
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY (2020)
Paraneoplastic syndromes in cholangiocarcinoma
Saad Ur Rahman et al.
WORLD JOURNAL OF HEPATOLOGY (2020)
Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma
Paola Bertuccio et al.
JOURNAL OF HEPATOLOGY (2019)
Surgery for cholangiocarcinoma
Umberto Cillo et al.
LIVER INTERNATIONAL (2019)
REVERCE: a randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for previously treated metastatic colorectal cancer patients
K. Shitara et al.
ANNALS OF ONCOLOGY (2019)
Analysis across multiple tumor types provides no evidence that mutant p53 exerts dominant negative activity
Ashkan Shahbandi et al.
NPJ PRECISION ONCOLOGY (2019)
Cholangiocarcinoma - evolving concepts and therapeutic strategies
Sumera Rizvi et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Cholangiocytes in the pathogenesis of primary sclerosing cholangitis and development of cholangiocarcinoma
Brian K. Chung et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2018)
90Y Radioembolization for Hepatic Malignancy in Patients with Previous Biliary Intervention: Multicenter Analysis of Hepatobiliary Infections
Kavi K. Devulapalli et al.
RADIOLOGY (2018)
Elevated levels of circulating osteopontin are associated with a poor survival after resection of cholangiocarcinoma
Sven H. Loosen et al.
JOURNAL OF HEPATOLOGY (2017)
Intrahepatic cholangiocarcinoma: current management and emerging therapies
Amir A. Rahnemai-Azar et al.
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY (2017)
The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more personalized approach to cancer staging
Mahul B. Amin et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2017)
Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)
Jesus M. Banales et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2016)
Prognostic impact of lymph node metastasis in distal cholangiocarcinoma
M. Kiriyama et al.
BRITISH JOURNAL OF SURGERY (2015)
Impact of tissue type and content of neoplastic cells of samples on the quality of epidermal growth factor receptor mutation analysis among patients with lung adenocarcinoma
Panagiotis Paliogiannis et al.
MOLECULAR MEDICINE REPORTS (2015)
Circulating Oncometabolite 2-Hydroxyglutarate Is a Potential Surrogate Biomarker in Patients with Isocitrate Dehydrogenase-Mutant Intrahepatic Cholangiocarcinoma
Darrell R. Borger et al.
CLINICAL CANCER RESEARCH (2014)
Mutations of isocitrate dehydrogenase 1 and 2 in intrahepatic cholangiocarcinoma
Alexandra R. Grassian et al.
CURRENT OPINION IN GASTROENTEROLOGY (2014)
Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma
John Bridgewater et al.
JOURNAL OF HEPATOLOGY (2014)
Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer
Supriya K. Saha et al.
NATURE (2014)
Mutation Profiling in Cholangiocarcinoma: Prognostic and Therapeutic Implications
Chaitanya R. Churi et al.
PLOS ONE (2014)
Cholangiocarcinoma: Molecular Pathways and Therapeutic Opportunities
Sumera Rizvi et al.
SEMINARS IN LIVER DISEASE (2014)
Clinicopathologic Analysis of Combined Hepatocellular-Cholangiocarcinoma According to the Latest WHO Classification
Jun Akiba et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2013)
Evolution of Surgical Treatment for Perihilar Cholangiocarcinoma A Single-Center 34-Year Review of 574 Consecutive Resections
Masato Nagino et al.
ANNALS OF SURGERY (2013)
Identification of Targetable FGFR Gene Fusions in Diverse Cancers
Yi-Mi Wu et al.
CANCER DISCOVERY (2013)
Cholangiocarcinoma and dominant strictures in patients with primary sclerosing cholangitis: a 25-year single-centre experience
Michael H. Chapman et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2012)
Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update
Shahid A. Khan et al.
GUT (2012)
Histological diversity in cholangiocellular carcinoma reflects the different cholangiocyte phenotypes
Mina Komuta et al.
HEPATOLOGY (2012)
Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma
Benjamin R. Kipp et al.
HUMAN PATHOLOGY (2012)
Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma
William C. Palmer et al.
JOURNAL OF HEPATOLOGY (2012)
Rising trends in cholangiocarcinoma: Is the ICD classification system misleading us?
Shahid A. Khan et al.
JOURNAL OF HEPATOLOGY (2012)
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype
Sevin Turcan et al.
NATURE (2012)
Frequent Mutation of Isocitrate Dehydrogenase (IDH)1 and IDH2 in Cholangiocarcinoma Identified Through Broad-Based Tumor Genotyping
Darrell R. Borger et al.
ONCOLOGIST (2012)
Cancer Surveillance in Patients With Primary Sclerosing Cholangitis
Nataliya Razumilava et al.
HEPATOLOGY (2011)
Metabolic Syndrome Increases the Risk of Primary Liver Cancer in the United States: A Study in the SEER-Medicare Database
Tania M. Welzel et al.
HEPATOLOGY (2011)
Risk Factors for Cholangiocarcinoma
Gia L. Tyson et al.
HEPATOLOGY (2011)
Phase II Study of the Mitogen-Activated Protein Kinase 1/2 Inhibitor Selumetinib in Patients With Advanced Hepatocellular Carcinoma
Bert H. O'Neil et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Combination of gemcitabine and cisplatin for biliary tract cancer: A platform to build on
Nataliya Razumilava et al.
JOURNAL OF HEPATOLOGY (2011)
Is Para-aortic Lymph Node Metastasis a Contraindication for Radical Resection in Biliary Carcinoma?
Yoshiaki Murakami et al.
WORLD JOURNAL OF SURGERY (2011)
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer.
Juan Valle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Fibroblast growth factor signalling: from development to cancer
Nicholas Turner et al.
NATURE REVIEWS CANCER (2010)
Crystal Structures of MEK1 Binary and Ternary Complexes with Nucleotides and Inhibitors
Thierry O. Fischmann et al.
BIOCHEMISTRY (2009)
Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma
D. Yoshikawa et al.
BRITISH JOURNAL OF CANCER (2009)
Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy
E. Martinelli et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2009)
Burden of Digestive Diseases in the United States Part III: Liver, Biliary Tract, and Pancreas
James E. Everhart et al.
GASTROENTEROLOGY (2009)
Risk of Hepatobiliary and Pancreatic Cancers After Hepatitis C Virus Infection: A Population-Based Study of US Veterans
Hashem B. El-Serag et al.
HEPATOLOGY (2009)
EASL Clinical Practice Guidelines: Management of cholestatic liver diseases
Ulrich Beuers et al.
JOURNAL OF HEPATOLOGY (2009)
Evidence-Based Approach to Cholangiocarcinoma: A Systematic Review of the Current Literature
Murad Aljiffry et al.
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS (2009)
Hepatitis B virus infection and intrahepatic cholangiocarcinoma in Korea: A case-control study
Tae Y. Lee et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2008)
The epidermal growth factor receptor family: Biology driving targeted therapeutics
M. J. Wieduwilt et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2008)
Risk factors for intrahepatic cholangiocarcinoma: A case-control study in China
Yan-Ming Zhou et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2008)
Opisthorchis viverrini:: The carcinogenic human liver fluke
Natthawut Kaewpitoon et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2008)
Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma
D. Yoshikawa et al.
BRITISH JOURNAL OF CANCER (2008)
Cholangiocarcinoma - Thirty-one-year experience with 564 patients at a single institution
Michelle L. DeOliveira et al.
ANNALS OF SURGERY (2007)
Risk factors for intrahepatic cholangiocarcinoma in a low-risk population: A nationwide case-control study
Tania M. Welzel et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
Racial and ethnic variations in the epidemiology of intrahepatic cholangiocarcinoma in the United States
Luciana McLean et al.
LIVER INTERNATIONAL (2006)
Liver stem cells and their implication in hepatocellular and cholangiocarcinoma
T Roskams
ONCOGENE (2006)
Risk factors of intrahepatic cholangiocarcinoma in the United States: A case-control study
YH Shaib et al.
GASTROENTEROLOGY (2005)
Relation of hepatolithiasis to helminthic infestation
MH Huang et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2005)
Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase?
YH Shaib et al.
JOURNAL OF HEPATOLOGY (2004)
Structures of human cytosolic NADP-dependent isocitrate dehydrogenase reveal a novel self-regulatory mechanism of activity
X Xu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Hepatitis C virus infection as a likely etiology of intrahepatic cholangiocarcinoma
S Yamamoto et al.
CANCER SCIENCE (2004)
The epidemiology of cholangiocarcinoma
Y Shaib et al.
SEMINARS IN LIVER DISEASE (2004)
Cholangiocarcinoma in primary sclerosing cholangitis:: Risk factors and clinical presentation
KM Boberg et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2002)
Cholangiocarcinoma: Recent progress. Part 1: Epidemiology and etiology
K Okuda et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2002)
Intrahepatic cholangiocarcinoma and hepatitis C and B virus infection, alcohol intake, and hepatolithiasis: a case-control study in Italy
F Donato et al.
CANCER CAUSES & CONTROL (2001)
Lymph node metastasis from hilar cholangiocarcinoma: Audit of 110 patients who underwent regional and paraaortic node dissection
Y Kitagawa et al.
ANNALS OF SURGERY (2001)
分享论文
